Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the Phase III registered clinical trial of the national Class 1 innovative drug TQC2731 injection “TSLP monoclonal antibody” independently developed by the group subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), for maintenance treatment of chronic sinusitis with nasal polyps (CrSwnP) has recently completed the enrollment of all participants.

Zhitongcaijing · 4d ago
Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the Phase III registered clinical trial of the national Class 1 innovative drug TQC2731 injection “TSLP monoclonal antibody” independently developed by the group subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), for maintenance treatment of chronic sinusitis with nasal polyps (CrSwnP) has recently completed the enrollment of all participants.